Insights

Top 10 Pharmaceuticals Losing Exclusivity in the US in 2024

As the relentless march of time continues, pharmaceutical executives find themselves facing the inevitability of patent expirations and the subsequent entry of generic or biosimilar competition. This reality underscores the imperative for continual…